{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IVIg-placebo&page=2", "query": { "intervention": "IVIg-placebo", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 76, "total_pages": 8, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IVIg-placebo&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=IVIg-placebo&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-02T08:43:58.528Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05645107", "title": "A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hypogammaglobulinemia", "Bacterial Infections", "B-cell Chronic Lymphocytic Leukemia", "Multiple Myleoma", "Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Xembify", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Grifols Therapeutics LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 386, "start_date": "2022-12-26", "completion_date": "2029-08", "has_results": false, "last_update_posted_date": "2026-09-30", "last_synced_at": "2026-10-02T08:43:58.528Z", "location_count": 9, "location_summary": "Bullhead City, Arizona • Huntington Park, California • St. Petersburg, Florida + 6 more", "locations": [ { "city": "Bullhead City", "state": "Arizona" }, { "city": "Huntington Park", "state": "California" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Greenville", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05645107" }, { "nct_id": "NCT05952804", "title": "IVIG for Infection Prevention After CAR-T-Cell Therapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hematologic Malignancies" ], "interventions": [ { "name": "Immune Globulin Infusion (Human), 10% Solution", "type": "BIOLOGICAL" }, { "name": "Anti-CD19 CAR T Cells Preparation", "type": "BIOLOGICAL" }, { "name": "Saline", "type": "OTHER" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Survey Administration", "type": "OTHER" }, { "name": "Electronic Health Record Review", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "PROCEDURE" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2024-06-10", "completion_date": "2028-07-31", "has_results": false, "last_update_posted_date": "2026-06-29", "last_synced_at": "2026-10-02T08:43:58.528Z", "location_count": 7, "location_summary": "Duarte, California • Miami, Florida • Tampa, Florida + 4 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05952804" }, { "nct_id": "NCT00105183", "title": "EZ-2053 in the Prophylaxis of Acute Pulmonary Allograft Rejection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Obstructive Pulmonary", "Idiopathic Pulmonary Fibrosis", "Cystic Fibrosis", "Bronchiectasis", "Pulmonary Vascular Disease" ], "interventions": [ { "name": "Placebo", "type": "BIOLOGICAL" }, { "name": "EZ-2053", "type": "BIOLOGICAL" }, { "name": "EZ-2053 5mg/kg", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Neovii Biotech", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 223, "start_date": "2005-01", "completion_date": "2011-01", "has_results": true, "last_update_posted_date": "2012-06-11", "last_synced_at": "2026-10-02T08:43:58.528Z", "location_count": 15, "location_summary": "Los Angeles, California • San Francisco, California • Stanford, California + 11 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00105183" }, { "nct_id": "NCT01281969", "title": "Intravenous Immunoglobulin for PANDAS", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Obsessive-Compulsive Disorder", "Children", "Anxiety Disorder", "Autoimmune Disease", "PANDAS" ], "interventions": [ { "name": "Gamunex Intravenous Immunoglobulin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Mental Health (NIMH)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": "13 Years", "sex": "ALL", "summary": "4 Years to 13 Years" }, "enrollment_count": 48, "start_date": "2011-01", "completion_date": "2018-08-13", "has_results": true, "last_update_posted_date": "2020-03-17", "last_synced_at": "2026-10-02T08:43:58.528Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01281969" }, { "nct_id": "NCT00000935", "title": "An Evaluation of IV Gamma Globulin As a Method to Improve Kidney Transplant Survival in Patients With End-Stage Renal Disease Who Are Highly Sensitized to Transplant Antigens", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "End-Stage Renal Disease", "Kidney Transplantation" ], "interventions": [ { "name": "Intravenous immune globulin (IVIG)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 100, "start_date": null, "completion_date": "2003-06", "has_results": false, "last_update_posted_date": "2017-01-11", "last_synced_at": "2026-10-02T08:43:58.528Z", "location_count": 1, "location_summary": "Rockville, Maryland", "locations": [ { "city": "Rockville", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00000935" }, { "nct_id": "NCT04510428", "title": "OSIG-eye Drops Treatment for Dry Eye Disease", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Dry Eye" ], "interventions": [ { "name": "Ocular Surface Immune Globulin (OSIG)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Illinois at Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2023-05-15", "completion_date": "2024-01-20", "has_results": false, "last_update_posted_date": "2023-05-23", "last_synced_at": "2026-10-02T08:43:58.528Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04510428" }, { "nct_id": "NCT04153422", "title": "IVIG in the Treatment of Autoimmune Small Fiber Neuropathy With TS-HDS, FGFR-3, or Plexin D1 Antibodies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Small Fiber Neuropathy", "Autoimmune Small Fiber Neuropathy", "Inflammatory Polyneuropathy", "Immune-Mediated Neuropathy" ], "interventions": [ { "name": "Panzyga IVIG", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Endeavor Health", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2023-12-15", "completion_date": "2028-02-28", "has_results": false, "last_update_posted_date": "2026-01-09", "last_synced_at": "2026-10-02T08:43:58.528Z", "location_count": 1, "location_summary": "Glenview, Illinois", "locations": [ { "city": "Glenview", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04153422" }, { "nct_id": "NCT04138485", "title": "Efficacy and Safety of IgPro10 in Adults With Systemic Sclerosis (SSc)", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diffuse Cutaneous Systemic Sclerosis" ], "interventions": [ { "name": "IgPro10", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "CSL Behring", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2019-12-20", "completion_date": "2020-09-16", "has_results": false, "last_update_posted_date": "2020-11-17", "last_synced_at": "2026-10-02T08:43:58.528Z", "location_count": 20, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 15 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04138485" }, { "nct_id": "NCT00760435", "title": "Infliximab Plus Intravenous Immunoglobulin for the Primary Treatment of Kawasaki Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Kawasaki Disease" ], "interventions": [ { "name": "Infliximab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Diego", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Weeks", "maximum_age": "17 Years", "sex": "ALL", "summary": "4 Weeks to 17 Years" }, "enrollment_count": 196, "start_date": "2009-03", "completion_date": "2012-10", "has_results": true, "last_update_posted_date": "2014-11-24", "last_synced_at": "2026-10-02T08:43:58.528Z", "location_count": 2, "location_summary": "La Jolla, California • Columbus, Ohio", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00760435" }, { "nct_id": "NCT00110708", "title": "Safety and Efficacy Study in the Treatment of Intestinal Problems Associated With Autism", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Autism", "Autistic Disorder", "Child Development Disorders, Pervasive", "Gastrointestinal Diseases", "Signs and Symptoms, Digestive" ], "interventions": [ { "name": "Oralgam (human immunoglobulin)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "PediaMed Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "2 Years to 18 Years" }, "enrollment_count": 120, "start_date": "2005-04", "completion_date": "2006-06", "has_results": false, "last_update_posted_date": "2006-02-22", "last_synced_at": "2026-10-02T08:43:58.528Z", "location_count": 22, "location_summary": "Phoenix, Arizona • Sacramento, California • Gainesville, Florida + 17 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Sacramento", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00110708" } ] }